期刊文献+

乳腺癌外科治疗的个体化精准之路 被引量:14

下载PDF
导出
摘要 近20年乳腺癌治疗理念更新迭代,多学科综合诊疗模式已经取得长足的进步,外科治疗仍然是早期乳腺癌综合治疗中的重要组成部分。乳腺癌外科治疗虽尚未真正发展到基于基因检测的精准时代,影像检查技术的进步、保乳手术的开展、前哨淋巴结活检的应用和放疗的推广已经将乳腺癌外科治疗推上个体化精准之路。本文针对近2年美国临床肿瘤学学会会议、St.Gallen会议和圣安东尼奥乳腺癌研讨会上乳腺癌外科治疗领域的热点问题,结合临床应用实践和指南更新,探讨乳腺癌外科的个体化精准治疗。
出处 《实用肿瘤杂志》 CAS 2018年第4期377-382,共6页 Journal of Practical Oncology
基金 浙江省自然科学基金(LY14H160030)
  • 相关文献

参考文献4

二级参考文献45

  • 1Ravelli A, Reuben JM, Lanza F, et al. Breast cancer circu- lating biomarkers: advantages, drawbacks, and new in- sights [ J ] Turnout Biol,2015,36 (9) :6653 - 6665.
  • 2Lee JS, Park S, Park JM,et al. Elevated levels of preoper- ative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer[ J]. Ann On- en1,2013,24(5 ) : 1225 - 1231.
  • 3Lee JS, Park S, Park JM, et al. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers [ J ]. Breast Cancer Res Treat, 2013,141 ( 3 ) :477 - 484.
  • 4Sturgeon CM, Dully M J, Stenman UH, et al. National A- cademy of Clinical Biochemistry laboratm'y medicine prac- tice guidelines for use of tumor markers in testicular, pros- tate, colorectal, breast, and ovarian cancers [ J ]. Clin Chem,2008,54(12) :el I -79.
  • 5Wang T, Zhou J, Zhang S, et al. Meaningful interpretation of serum HER2 ECD levels requires clear patient clinical background,and sel-ces several functions in the efficient management of breast eancer patients [ J ]. Clin Chim Ae- ta,2016,458:23 - 29.
  • 6Ludovini V, Gori S, Colozza M, et al. Evaluation of serum HER2 extracellular domain in early breast cancer pa- tients:correlation with elinicopathological parameters and survival [ J ]. Ann Oncol, 2008,19 ( 5 ) : 883 - 890.
  • 7Fehln T,Jiger W, Krimer S, et al. Prognostic significance f serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer [ J ]. Antieaneer Res, 2004, 24 (3b) : 1987 - 1992.
  • 8Colomer tl, Llombart-Cussac A, Lluch A, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase 1I trial and predictive value of HER2 extraeellular domain [ J ]. Ann Oncol, 2004,15 ( 2 ) : 201 - 206.
  • 9Muller V,Witzel I, Luck HJ, et al. Prognostic and predic- tive impact of the HER-2/nen extraeellular domain (ECD) in the serum of patients treated with chemothera- py for metastatic breast cancer [ J J. Breast Caneer Res Treat, 2004,86 ( 1 ) : 9 - 18.
  • 10Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her- 2/neu level predicts decreased response to hormone ther- apy in metastatic breast cancer[ J ]. J Clin Oneol,2002, 20(6) :1467 - 1472.

共引文献1190

同被引文献111

引证文献14

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部